🟢 Biovie is trading 5.8% up in after-hours trading with no fresh catalyst identified

Biovie is trading at $1.82, up +5.81% in after-hours trading, rebounding after a prior decline.

• Biovie declined 14.63% to $1.75 on September 15.
• The Phase 2 ADDRESS-LC trial found no statistically significant endpoint in the overall 203-patient population, despite numerical improvement on 21 of 22 endpoints.
• September 16 coverage announced a September 23 investor webinar; no fresh catalyst directly explaining the after-hours gain was identified.